B Cell Lymphoma
Conference Coverage
KTE-X19 produces highest response rate in MCL subgroup
ORLANDO – The CAR T-cell therapy produced the highest reported response rate in mantle cell lymphoma patients who have failed treatment with a...
Conference Coverage
An off-the-shelf drug to rival CAR T cells: ‘very exciting’
ORLANDO – Mosunetuzumab is a bispecific antibody that targets both CD3 and CD20. It was tested in a phase 1/1b trial among patients with relapsed/...
Conference Coverage
Orelabrutinib could be ‘preferred’ BTK inhibitor for MCL
ORLANDO – Orelabrutinib produced an 86% response rate in a phase 2 trial and appears to be safer than ibrutinib.
Conference Coverage
Efficacy of postvenetoclax therapy may depend on prior agent exposure in CLL
ORLANDO – The multicenter study was aimed at addressing the knowledge gap around what therapy to use after venetoclax.
Conference Coverage
Off-the-shelf cellular therapy shows promise in the lab
ORLANDO – Findings from this preclinical research support moving forward with a phase 1 study of the therapy, as monotherapy or combined with...
News
Newly identified genetic changes contribute to transformation of follicular lymphoma
The case of a 36-year-old man whose low-grade follicular lymphoma transformed to B-ALL/LBL about 1 year after diagnosis sheds lights on the...
News
SOX11 shows value as diagnostic marker in MCL
The meta-analysis evaluated the diagnostic accuracy of SOX11 immunohistochemistry in mantle cell lymphoma.
News
Acalabrutinib may outperform other targeted therapies in MCL
The drug showed advantages over targeted monotherapies but was similar to rituximab-based combinations.
News
FDA approves acalabrutinib for CLL, SLL treatment
The approval was made as part of Project Orbis, a collaboration among the FDA, the Australian Therapeutic Goods Administration, and Health Canada...
News
Frontline ibrutinib saves money over chemoimmunotherapy
An analysis of claims data for more than 1,000 patients with chronic lymphocytic leukemia shows that ibrutinib monotherapy is a less expensive...